Nyrada AGM 2024 Chair’s Address
Good morning, ladies and gentlemen. My name is Dr Gisela Mautner. I am one of the non-executive directors of Nyrada… Read more
Nyrada Successfully Raises $3.36 Million via Placement
Highlights: •Nyrada has successfully raised $3.36 million of new equity capital (before costs) by way of a Placement to institutional,… Read more
Nyrada Inc Investor Presentation
Nyrada Inc Investor Presentation
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: •Nyrada successfully completes Good Laboratory Practice safety studies of lead drug candidate NYR-BI03. •Preclinical efficacy study showed NYR-BI03 provided… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: •Nyrada successfully completes Good Laboratory Practice safety studies of lead drug candidate NYR-BI03. •Preclinical efficacy study showed NYR-BI03 provided… Read more
NYR – Supplementary NYR-BI03 Studies Confirm Strong Cardioprotection
Highlights: •Nyrada successfully completes supplementary preclinical studies, further supporting NYR-BI03’s efficacy in treating ischemia-reperfusion injury associated with heart attack. •Echocardiography… Read more
Nyrada Successfully Completes Safety Studies Ahead of Phase I Clinical Trial
Nyrada Inc (ASX:NYR) has announced the successful completion of their Good Laboratory Practice (GLP) safety studies on its lead drug… Read more
Nyrada Inc – Brain Injury Program GLP Studies Further Update 6
Highlights: • In vivo micronucleus study completed providing further data to support safety of Nyrada’s lead Brain Injury drug candidate… Read more
Nyrada’s Lead Drug Candidate Demonstrates Significant Cardioprotection
On Tuesday morning, Nyrada Inc. (ASX: NYR) released a significant announcement about a potential new indication for its lead drug… Read more
